The lines of connection between mental health and opioid addiction

The intersection of mental health and opioid addiction represents a growing clinical area of focus¹, with significant implications for morbidity, mortality, and care delivery across the UK.

Patients with opioid use disorder (OUD) frequently present with co-occurring psychiatric conditions², including depression, anxiety, PTSD, and complex trauma histories – complicating diagnosis, treatment, and long-term recovery outcomes³.

In the UK, prescribing rates for opioid medications remain high⁴, particularly among patients with chronic pain and untreated or under-recognised mental health conditions. Meanwhile, rates of drug-related deaths – especially those involving opioids, which at over 2,500 in 2023 constituted more than half of all drug-related mortalities – continue to rise⁵.

Statistics like these reinforce the need for an integrated, evidence-based approach to treating comorbid mental and substance use disorders. As part of that, the clinical community continues to explore the connection between mental health and opioid addiction.

Know someone struggling to manage opioid use? Make a referral now →

Epidemiology of opioid addiction and mental health disorders

The co-occurrence of opioid use disorder (OUD) and mental health conditions is well-documented across international and UK-based epidemiological studies⁶. In England, data from the BMC indicate that almost 60% of individuals in substance misuse treatment for opioids also present with comorbid mental health needs⁷: primarily depression, anxiety disorders, and post-traumatic stress disorder (PTSD).

Among primary care patients prescribed long-term opioids for chronic non-cancer pain, undiagnosed or undertreated psychiatric morbidity remains a significant driver of misuse and eventual dependence⁸.

A recent analysis by Public Health England (PHE) further noted that people with multiple risk factors or vulnerabilities – such as a turbulent, high-octane professional lifestyle, or a history of adverse childhood experiences – demonstrate markedly elevated tendencies toward both substance use and common mental disorders⁹.

Notably, opioid misuse often follows initial exposure through prescribed opioid analgesics¹⁰, blurring the distinction between iatrogenic dependence and illicit opioid use. This is especially relevant in populations with concurrent mental health disorders, where maladaptive coping mechanisms and neurobiological vulnerabilities may predispose individuals to rapid development of OUD.

Neurobiological and psychopathological links

The relationship between mental health disorders and opioid addiction is underpinned by shared neurobiological substrates and overlapping pathophysiological mechanisms. Both involve:

• Dysregulation of the mesolimbic dopamine pathway¹¹,
• Impairments in prefrontal cortical function¹², and
• Heightened reactivity of the hypothalamic-pituitary-adrenal (HPA) axis¹³ – particularly in individuals with a history of early trauma or chronic stress.

Opioids exert their effects through binding to mu-opioid receptors (MORs) in the central nervous system, modulating both nociception and affective states¹⁴. In individuals with mood or anxiety disorders, endogenous opioid system dysfunction may contribute to emotional dysregulation¹⁵ and a heightened reinforcing response to exogenous opioids: driving self-medication patterns and accelerating dependence.

Moreover, structural and functional neuroimaging studies have revealed alterations in amygdala, anterior cingulate cortex, and ventromedial prefrontal brain regions in both OUD and depression¹⁶, suggesting common neuroadaptive processes.

From a psychopathological perspective, the bi-directional relationship between OUD and mental illness complicates traditional diagnostic boundaries.

Chronic pain, mental illness, and prescription opioids

The management of chronic non-cancer pain is a key driver of opioid prescribing in the UK¹⁷. Yet in patients with co-occurring mental illness, clinical decision-making is further complicated by heightened pain sensitivity, catastrophisation, and risk of medication misuse. The biopsychosocial model¹⁸ remains central to comprehensive assessment and ongoing treatment.

Key considerations

Psychiatric comorbidity as a predictor of opioid misuse

→ Individuals with mood or anxiety disorders are significantly more likely to escalate from prescribed use to misuse¹⁹. In particular, pain-related depression is independently associated with non-adherence and early refill behaviour.

Prescribing practices and the risk of dependence

→ Long-term opioid prescribing (>3 months) is associated with increased odds of developing OUD²⁰, particularly in patients concurrently prescribed anxiolytics, hypnotics, or antidepressants.

Diagnostic challenges in complex presentations

→ Differentiating between opioid-induced hyperalgesia, untreated psychiatric distress, and genuine nociceptive pain requires nuanced evaluation. Poorly or mismanaged psychiatric symptoms can obscure accurate pain reporting and misguide treatment escalation.

Best practice approaches

• Multimodal pain management, integrating CBT for pain, graded exercise therapy, and non-opioid analgesics.
• In patients with psychiatric comorbidity, early psychiatric review is critical prior to initiating opioids.
• Where opioids are indicated, use the lowest effective dose for the shortest duration, with regular review of mental health status and risk indicators.

Evidence-based treatment approaches

Management of patients with co-occurring opioid use disorder (OUD) and mental health conditions requires an integrated, multimodal treatment strategy. Evidence supports a combination of pharmacotherapy, psychological intervention, and social support, tailored to individual diagnostic and functional needs.

Pharmacological interventions

• Opioid Agonist Therapy (OAT): first-line treatment for moderate to severe OUD includes methadone or buprenorphine. Both have been shown to reduce illicit opioid use, improve retention in treatment, and lower overdose risk²¹. Buprenorphine’s partial agonist profile offers a favourable safety profile in patients with comorbid depression and anxiety.
• Adjunctive psychotropics: antidepressants (e.g., SSRIs, SNRIs) and mood stabilisers may be indicated for comorbid major depressive disorder, bipolar disorder, or PTSD²². Caution is required due to pharmacodynamic interactions, especially during induction phases of OAT.
• Emerging agents: studies are investigating the role of extended-release naltrexone²³, particularly in populations with high relapse risk. However, induction remains challenging in those with poor detox adherence.

Psychological interventions

• Cognitive Behavioural Therapy (CBT): demonstrated efficacy in addressing maladaptive thought patterns, pain catastrophising, and relapse prevention²⁴.
• Integrated Dual Diagnosis Therapy: combines substance use and psychiatric treatment within a unified framework²⁵. Evidence supports improved outcomes compared to sequential or parallel treatment models.
• Trauma-informed approaches: essential for patients with a history of PTSD, early childhood adversity, or complex trauma. Focus on emotional regulation and resilience-building.

Final thoughts

The intersection of mental health disorders and opioid addiction presents complex clinical challenges that require comprehensive, evidence-based management²⁶.

Recognising the bidirectional relationship between opioid use disorder and psychiatric comorbidities is essential for improving patient outcomes. Accurate diagnosis, integrated, whole-person treatment approaches, and adherence to UK clinical guidelines optimise recovery trajectories and reduce morbidity and mortality associated with this dual diagnosis.

For healthcare practitioners, timely referral to specialist addiction and mental health services is critical. Early intervention, multidisciplinary collaboration, and ongoing monitoring ensure that both mental health and substance use disorders are fully addressed – ultimately enhancing long-term wellbeing.

Make a referral or contact our specialist team today →

References

1. https://heal.nih.gov/news/stories/collaborative-care
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC10294295/
3. https://link.springer.com/article/10.1007/s00127-021-02199-2
4. https://www.sciencedirect.com/science/article/abs/pii/S2215036618304711#:~:text=Between%201998%20and%202016%2C%20opioid,000%20mg%20per%201000%20population).
5. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2023registrations#:~:text=Almost%20half%20of%20all%20drug,in%202022%20(2%2C261%20deaths).
6. https://pubmed.ncbi.nlm.nih.gov/30784952/
7. https://substanceabusepolicy.biomedcentral.com/articles/10.1186/s13011-023-00568-5#:~:text=For%20example%2C%20in%20England%2C%20approximately,health%20treatment%20need%20%5B7%5D.
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC6494200/
9. https://www.gov.uk/government/publications/health-matters-reducing-health-inequalities-in-mental-illness/health-matters-reducing-health-inequalities-in-mental-illness#:~:text=Alcohol%20and%20drug%20misuse%20are,improve%20health%20and%20enable%20choice.
10. https://www.bmj.com/content/360/bmj.j5790#:~:text=Conclusions%20Each%20refill%20and%20week,in%20the%20early%20postsurgical%20period.
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC6954000/
12. https://pmc.ncbi.nlm.nih.gov/articles/PMC5818385/#:~:text=Opioid%20actions%20have%20been%20extensively,alcohol%20bingeing%2C%20and%20food%20impulsivity.
13. https://pubmed.ncbi.nlm.nih.gov/19016181/
14. https://www.ncbi.nlm.nih.gov/books/NBK546642/
15. https://pmc.ncbi.nlm.nih.gov/articles/PMC6310672/#:~:text=A%20growing%20body%20of%20research%20indicates%20that,of%20mood%20and%20is%20dysregulated%20in%20MDD.&text=This%20emotional%20challenge%20was%20associated%20with%20reductions,reductions%20in%20negative%20and%20positive%20affect%2C%20respectively.
16. https://pmc.ncbi.nlm.nih.gov/articles/PMC4464814/#:~:text=Results,predict%20treatment%20response%20in%20depression.
17. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003270#:~:text=We%20found%20that%20between%202006,prescriptions%20for%20non%2Dcancer%20pain.
18. https://pmc.ncbi.nlm.nih.gov/articles/PMC6629782/
19. https://health-policy-systems.biomedcentral.com/articles/10.1186/s12961-020-00596-8#:~:text=Similarly%2C%20mental%20health%20factors%20are,prescription%20opioid%20misuse%20%5B26%5D.
20. https://www.ncbi.nlm.nih.gov/books/NBK553166/
21. https://www.sciencedirect.com/science/article/pii/S0376871623012747
22. https://pmc.ncbi.nlm.nih.gov/articles/PMC2851027/
23. https://www.ncbi.nlm.nih.gov/books/NBK534811/
24. https://harborlondon.com/how-cbt-for-opioid-use-disorder-helps-rebuild-lives/#:~:text=At%20Harbor%20London%2C%20CBT%20is,a%20renewed%20sense%20of%20agency.
25. https://www.sciencedirect.com/science/article/abs/pii/S0740547218302149
26. https://www.sciencedirect.com/science/article/abs/pii/S0376871622002885